Core Insights - Corcept Therapeutics received FDA approval for its leading drug candidate, Lifyorli, which is now ready for commercialization in the U.S. [3] - The approval allows Lifyorli to be used in combination with nab-paclitaxel to treat platinum-resistant stages of fallopian tube, primary peritoneal, and ovarian cancer [3] - Following the FDA approval, Corcept's stock experienced a gain of just under 9% over the week, despite a temporary double-digit increase as some investors took profits [2] Company Performance - Corcept's current market capitalization stands at $4.1 billion, with a current stock price of $37.60 [6][7] - The stock's 52-week range is between $28.66 and $117.33, indicating significant volatility [7] - The company has a gross margin of 98.30%, reflecting strong profitability potential [7] Analyst Insights - Wolfe Research analyst Kalpit Patel upgraded Corcept's stock recommendation from underperform to peerperform, influenced by the FDA approval of Lifyorli [4][5] - Patel expressed concerns that Corcept's existing drug, Korlym, which treats Cushing's syndrome, may hinder its growth potential [5] - Despite the analyst's cautious stance, there is optimism regarding Corcept's unique approach to drug development, particularly in the high-demand cancer treatment market [7]

Core Insights - Corcept Therapeutics (CORT) received FDA approval for its selective glucocorticoid receptor antagonist, Lifyorli (relacorilant), in combination with nab-paclitaxel for treating adult patients with platinum-resistant ovarian cancer [1][2] Group 1: FDA Approval and Clinical Data - Lifyorli is now the first FDA-approved selective glucocorticoid receptor antagonist for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, specifically for patients who have undergone one to three prior systemic treatments, including at least one with bevacizumab [2] - The approval was based on the pivotal phase III ROSELLA study, which met its dual primary endpoints of progression-free survival and overall survival [4] - The study demonstrated a 35% reduction in the risk of death for patients treated with Lifyorli plus nab-paclitaxel compared to nab-paclitaxel alone, with median overall survival of 16 months versus 11.9 months [5] - Additionally, there was a 30% reduction in the risk of disease progression for the combination treatment compared to nab-paclitaxel alone [6] Group 2: Market Impact and Revenue Diversification - Following the announcement, Corcept's shares increased by 19.7%, and the stock has risen 16.3% year-to-date, contrasting with a 4.9% decline in the industry [3] - The approval of Lifyorli is expected to diversify Corcept's revenue base, which has been heavily reliant on Korlym, currently approved for treating Cushing's syndrome [9] - Management believes Lifyorli is positioned to become a new standard-of-care treatment for platinum-resistant ovarian cancer, potentially reducing dependence on Korlym for revenues [9] Group 3: Future Developments - Corcept is also developing relacorilant for Cushing's syndrome, although it recently faced a setback with a complete response letter from the FDA regarding its new drug application for this indication [10][11] - The company is engaging with the FDA to find a path forward for relacorilant and has submitted a marketing authorization application to the European Medicines Agency for relacorilant in platinum-resistant ovarian cancer, with a decision expected in 2026 [13]

Core Insights - Corcept Therapeutics has seen its shares increase by approximately 11.7% since the last earnings report, outperforming the S&P 500 [1] Financial Performance - In Q4 2025, Corcept reported earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.27, and down from $0.26 per share in the same quarter last year [2] - Revenues for Q4 2025 rose by around 11.1% year over year to $202.1 million, but fell short of the Zacks Consensus Estimate of $254 million, primarily driven by sales of the Cushing's syndrome drug, Korlym [3] - Korlym revenue missed the model estimate of $250 million [4] - Research and development expenses decreased by 7.7% year over year to $64.9 million, while selling, general, and administrative expenses increased by approximately 56.1% year over year to $130.2 million, leading to a total operating expense increase of 26.2% year over year to $197.6 million [4] - As of December 31, 2025, cash and investments totaled $532.4 million, up from $524.2 million as of September 30, 2025 [4] Future Guidance - Corcept anticipates total revenues in the range of $900 million to $1 billion for 2026 [5] Estimate Trends - Recent estimates for Corcept have trended downward, with a consensus estimate shift of -12.66% over the past month [6] - The stock currently holds a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [8] Industry Comparison - Corcept operates within the Zacks Medical - Drugs industry, where competitor Madrigal (MDGL) has reported a revenue increase of 210.8% year over year, totaling $321.08 million in its last quarter [9] - Madrigal's EPS for the same period was -$2.57, an improvement from -$2.71 a year ago, and it has a Zacks Rank of 3 (Hold) [10]

Company Overview - Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage pharmaceutical company focused on developing treatments for serious disorders through cortisol modulation [5]. Financial Performance - For Q4 2025, Corcept reported revenue of $202.1 million, which was below the consensus estimate of $254.9 million [2]. - The full-year revenue for 2025 was reported at $761.4 million, falling short of the revised guidance range of $800 million to $850 million [2]. Prescription and Sales Growth - New prescriptions for Corcept's products increased by 61% year-over-year in 2025; however, actual tables sold only saw a 37% increase due to capacity constraints at the previous specialty pharmacy [3]. - Sales of Korlym were impacted during the transition to a new specialty pharmacy, Curant Rare, which began in November 2025 and was completed in January 2026 [3]. Future Guidance - The company provided revenue guidance for 2026 in the range of $900 million to $1 billion, indicating approximately 25% year-over-year growth at the midpoint [4]. - H.C. Wainwright has adjusted its price target for Corcept from $67 to $60, maintaining a Buy rating, reflecting a more cautious outlook for the Korlym franchise [4].

Core Insights - Corcept Therapeutics (CORT) reported Q4 2025 earnings of 20 cents per share, missing the Zacks Consensus Estimate of 27 cents, and down from 26 cents per share in the same quarter last year [1][6] - Revenues for Q4 increased by approximately 11.1% year over year to $202.1 million, but fell short of the Zacks Consensus Estimate of $254 million, with the revenue solely coming from product sales of the Cushing's syndrome drug, Korlym [1][3][6] - For the full year 2025, Corcept generated revenues of $761.4 million, an increase from $675 million in the previous year, but earnings per share decreased to 82 cents from $1.23 [7] Financial Performance - Q4 revenues from Korlym missed the model estimate of $250 million [3] - Research and development expenses decreased by 7.7% year over year to $64.9 million, while selling, general, and administrative expenses rose by approximately 56.1% year over year to $130.2 million [3] - Operating expenses increased by 26.2% year over year to $197.6 million in Q4 [3] - Cash and investments as of December 31, 2025, totaled $532.4 million, up from $524.2 million as of September 30, 2025 [3] Future Guidance - Corcept expects total revenues in the range of $900 million to $1 billion for 2026, with the Zacks Consensus Estimate at $1.03 billion [8] Pipeline Developments - Corcept is developing its lead pipeline candidate, relacorilant, for treating Cushing's syndrome and certain cancer indications, with an FDA decision on relacorilant in ovarian cancer expected in July 2026 [9][10] - The company received a complete response letter (CRL) from the FDA for relacorilant in Cushing's syndrome and is currently engaging with the FDA for next steps [11][12] - Corcept is also developing other pipeline candidates, including dazucorilant and miricorilant, for various conditions, with data readouts expected by the end of 2026 [14] Legal and Competitive Landscape - A recent ruling by the United States Court of Appeals upheld that Teva Pharmaceuticals' sale of a generic version of Korlym does not violate Corcept's patents [13] - Corcept currently holds a Zacks Rank of 4 (Sell), while competitors like Harmony Biosciences and Castle Biosciences have better rankings [15]

Financial Data and Key Metrics Changes - The company's revenue for 2025 was $761 million, an increase from $675 million in the previous year, with a revenue guidance for 2026 set at $900 million to $1 billion [3][4] - Net income for 2025 was $99.7 million, down from $141.2 million in the prior year [3] Business Line Data and Key Metrics Changes - The Cushing's syndrome business saw a 37% increase in tablets delivered compared to 2024, with a record number of new prescriptions and first-time prescribers [11][12] - Despite a 61% increase in new prescriptions, the gap between new prescriptions and tablets sold indicates capacity issues with the pharmacy vendor [11] Market Data and Key Metrics Changes - The transition to a new specialty pharmacy began in October 2025, aimed at addressing capacity issues and improving service delivery [12][55] - The company expects its Cushing's syndrome business to grow to at least $2 billion in annual revenue by the end of the decade, driven by increased recognition of hypercortisolism [14][26] Company Strategy and Development Direction - The company plans to appeal the FDA's decision regarding relacorilant and aims to make it available to patients as quickly as possible [10][26] - The focus remains on cortisol modulation to treat serious diseases, with ongoing research in oncology and metabolic conditions [15][21] Management's Comments on Operating Environment and Future Outlook - Management expressed surprise at the FDA's decision not to approve relacorilant, citing strong clinical trial data and alignment with FDA guidance during development [9][10] - The company is optimistic about the future growth of its Cushing's syndrome business and the potential for relacorilant to enhance treatment options [14][26] Other Important Information - The company reported cash and investments of $532 million as of December 31, 2025, reflecting stock repurchase activities [4] - The ROSELLA trial demonstrated a 35% reduction in risk of death for patients receiving relacorilant in combination with nab-paclitaxel, with a median overall survival increase of 4.1 months [19][20] Q&A Session Summary Question: Thoughts on the CRL and FDA's decision - Management believes the FDA may have shifted its expectations and plans to seek clarification in an upcoming meeting [34][38] Question: Guidance assumptions regarding Korlym - The net price for Korlym through the AG is about a 30% discount, with expectations for pricing pressures in 2026 [40] Question: Likelihood of running a randomized trial for relacorilant - Management indicated that the identification and treatment of hypercortisolism is crucial, but the path forward in clinical development remains uncertain [41][42] Question: Confidence in resolving supply chain issues - The transition to a new pharmacy partner has shown promising results, with improvements in service delivery metrics [55][56] Question: Safety profile of relacorilant - The safety profile remains consistent with previous analyses, showing no significant increases in ALT levels compared to nab-paclitaxel alone [60][62] Question: Impact of KEYTRUDA on treatment options - Management noted that KEYTRUDA's approval is limited by biomarker expression, but there is interest in maintaining treatment options for patients [64]

Financial Data and Key Metrics Changes - The company's revenue for 2025 was $761 million, an increase from $675 million in the previous year, with a revenue guidance for 2026 set at $900 million to $1 billion [3][4] - Net income for 2025 was $99.7 million, down from $141.2 million in the prior year [3] Business Line Data and Key Metrics Changes - The Cushing's syndrome business saw a 37% increase in tablet deliveries compared to 2024, with a record number of new prescriptions and first-time prescribers [11][12] - Despite a 61% increase in new prescriptions, the gap between new prescriptions and tablets sold indicates capacity issues with the pharmacy vendor [11] Market Data and Key Metrics Changes - The company transitioned to a new specialty pharmacy in October 2025 to address capacity issues, which has shown promising signs of improved performance [12][56] - The Cushing's syndrome business is expected to grow to at least $2 billion in annual revenue by the end of the decade, driven by increased recognition of hypercortisolism [14][26] Company Strategy and Development Direction - The company plans to appeal the recent court ruling against its patent for Korlym and is focused on making relacorilant available to patients as quickly as possible [4][10] - The company is optimistic about the potential of relacorilant in treating various solid tumors and is exploring its use in combination with other anticancer therapies [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed surprise at the FDA's decision not to approve relacorilant, citing strong clinical trial data and a history of collaboration with the FDA [5][10] - The company is confident in its future growth, particularly in the Cushing's syndrome market, and anticipates significant demand as findings from recent studies are recognized by physicians [26][28] Other Important Information - The company reported cash and investments of $532 million as of December 31, 2025, reflecting a stock repurchase program [4] - The ROSELLA trial demonstrated a 35% reduction in the risk of death for patients receiving relacorilant in combination with nab-paclitaxel, with a median overall survival increase of 4.1 months [19][20] Q&A Session Questions and Answers Question: Thoughts on the CRL and future trials for relacorilant - Management believes the FDA may have shifted its expectations and plans to clarify this in an upcoming meeting [30][34] - The company is considering running a randomized trial for relacorilant in type 2 diabetes and hypertensive patients, but no definitive path has been established yet [41] Question: Guidance assumptions for Korlym - The net price for Korlym through the AG is about a 30% discount, with expectations for 2026 indicating a stabilization in pricing pressures [31][40] Question: Supply chain issues and safety data - The transition to a new pharmacy partner has improved metrics, and management is confident in their ability to meet future demand [55][56] - Safety data from the ROSELLA trial shows no significant increases in ALT levels compared to nab-paclitaxel alone, indicating a favorable safety profile [60][62] Question: Impact of KEYTRUDA on the market - Management noted that KEYTRUDA's approval is limited to specific biomarker expressions, and there is interest in maintaining treatment options for patients [64]

Financial Data and Key Metrics Changes - The company's revenue for 2025 was $761 million, an increase from $675 million in the previous year, with a revenue guidance for 2026 set between $900 million and $1 billion [3][4] - Net income for 2025 was $99.7 million, down from $141.2 million in the prior year [3] Business Line Data and Key Metrics Changes - The Cushing's syndrome business saw a record number of new prescriptions and a 37% increase in tablets delivered compared to 2024, despite a 61% increase in new prescriptions indicating capacity issues with the pharmacy vendor [11][12] - The transition to a new specialty pharmacy began in October 2025, which is expected to resolve previous capacity issues and improve performance [12] Market Data and Key Metrics Changes - The company anticipates its Cushing's syndrome business to grow to at least $2 billion in annual revenue by the end of the decade, driven by increased recognition of hypercortisolism and the approval of relacorilant [14][25] Company Strategy and Development Direction - The company is focused on cortisol modulation to treat serious diseases, with ongoing research in oncology and metabolic conditions [15][16] - The ROSELLA trial demonstrated significant benefits for patients with platinum-resistant ovarian cancer, leading to expectations of relacorilant becoming a new standard of care [19][20] - The company is exploring the use of glucocorticoid receptor antagonism in combination with other therapies, including immunotherapy and androgen deprivation therapy [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed surprise at the FDA's decision not to approve relacorilant, citing strong clinical data and alignment with FDA guidelines during the development process [10][33] - The company plans to meet with the FDA to understand the reasoning behind the decision and explore options for moving forward [10][37] Other Important Information - The company has completed the MOMENTUM trial, which examines hypercortisolism in patients with resistant hypertension, with results expected to be announced soon [17] - The company is also advancing its proprietary compounds for various conditions, including metabolic dysfunction-associated steatohepatitis (MASH) and amyotrophic lateral sclerosis (ALS) [22][24] Q&A Session Summary Question: Thoughts on the CRL and potential randomized trials for relacorilant - Management believes the FDA may have shifted its criteria for approval, expressing confidence in the data supporting relacorilant [33][36] - The likelihood of running a randomized trial for relacorilant in type 2 diabetes or hypertensive patients is uncertain, but management emphasizes the importance of identifying and treating hypercortisolism [40][41] Question: Guidance assumptions regarding Korlym and pricing - The net price for Korlym through the AG is approximately a 30% discount, with expectations for pricing pressures in 2026 [39] Question: Supply chain issues and confidence in new pharmacy partner - Management is confident in the new pharmacy's capabilities, citing their expertise and ability to scale operations effectively [54][55] Question: Safety profile of relacorilant and comparison with nab-paclitaxel - The safety profile of relacorilant in the ROSELLA trial is consistent with previous analyses, showing no significant added toxicity compared to nab-paclitaxel [60][61] Question: Impact of KEYTRUDA on treatment options - Management notes that KEYTRUDA's approval is limited to specific patient populations, and there is interest among oncologists in maintaining treatment options that include relacorilant [63]

Core Insights - Polen Capital's fourth-quarter investor letter for the Polen 5Perspectives Small Growth Strategy reported a return of -1.3% gross and -1.5% net of fees, underperforming the Russell 2000 Growth Index which returned 1.2% [1] - The small-cap asset class gained attention due to declining interest rates and improving earnings growth, with a notable focus on biotech as a major performer during the quarter [1] - The strategy's name was changed to emphasize the significance of the 5 viewpoints framework in investing [1] Company Focus: Corcept Therapeutics Incorporated - Corcept Therapeutics Incorporated (NASDAQ:CORT) is highlighted as a biopharmaceutical company developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders [2][3] - As of February 23, 2026, Corcept's stock closed at $35.34 per share, with a one-month return of -22.56% and a 52-week loss of 42.82% [2] - Corcept has a market capitalization of $3.724 billion [2] - The company is at an inflection point, expanding beyond its core indication with promising Phase 3 data for relacorilant in adrenal cancer and other indications, despite facing pressure from slower Korlym sales growth and uncertainty around pipeline approvals [3]

Core Viewpoint - Corcept Therapeutics is facing significant pressure on its stock due to legal rulings that increase competition from generic versions of its flagship drug, Korlym, leading to heightened uncertainty regarding future revenue and necessitating diversification efforts [2][4][5]. Group 1: Legal and Competitive Landscape - An appeals court upheld a ruling against Corcept, stating that there was no evidence that doctors would use the specific dosing methods claimed by Corcept, which diminishes the protective effect of its patents [2][3][4]. - The ruling allows Teva's generic version of Korlym to enter the market sooner than expected, increasing competitive pressure on Corcept's revenue from this drug [4][5]. Group 2: Stock Performance and Market Sentiment - Corcept's shares are currently trading 24.4% below their 20-day simple moving average and 52.9% below their 100-day simple moving average, indicating a bearish trend [6]. - Over the past year, the stock has decreased by 57.55%, and it is closer to its 52-week lows than highs, reflecting ongoing weakness in market sentiment [6]. Group 3: Earnings and Analyst Outlook - Corcept is scheduled to report earnings on February 24, which could provide further insights into its financial health [7]. - The stock currently carries a Buy rating with an average price target of $100.00, despite recent sharp declines in share price [8]. - Analysts have adjusted their earnings per share estimate to 31 cents and revenue estimate to $254.72 million, indicating a positive outlook despite current challenges [8].